secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0001549595-25-000108
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix begins investor meetings with updated clinical plans for bexobrutideg Phase 1 trial
--------------------------------------------------------------------------------

- Company presenting updated development plans for bexobrutideg (NX-5948), an oral BTK degrader.
- Phase 1 trial ongoing in patients with relapsed/refractory B cell malignancies.
- Investor presentation dated September 3, 2025, furnished as Exhibit 99.1.
- Specific clinical data updates not detailed in the 8-K filing text.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000108/0001549595-25-000108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000108/nrix-20250903.htm
  HTML page:      https://secwatch.observer/filing/0001549595-25-000108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer